Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
GAITHERSBURG, Md., Jan. 10, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has received a favorable private letter ruling from the Internal Revenue Service related to the planned spin-off of its biosciences business. Subject to its terms, the ruling confirms that certain aspects of the planned transaction, including those related to the qualification of the business as an active trade or business, will not preclude the spin-off from qualifying as tax-free to Emergent and its stockholders.
Daniel J. Abdun-Nabi, President and Chief Executive Officer of Emergent BioSolutions stated, “Since announcing our intention to pursue a tax-free spin-off of our biosciences business last August, we have chosen Aptevo Therapeutics Inc. as the new company’s name, identified its board of directors, and now received a favorable IRS ruling. These are significant milestones towards completing the spin-off. Our next steps include selecting the Aptevo senior management team, filing with and obtaining clearance from the Securities and Exchange Commission of a Form 10 Registration Statement, and completing the distribution of Aptevo shares to our stockholders, which we expect to be completed by the middle of 2016.”
About Emergent BioSolutions
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding the planned spin-off of our biosciences business, the timing of any such spin-off, and any other statements containing the words "believes", "expects", "anticipates", "intends", "plans", "forecasts", "estimates" and similar expressions are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including whether the planned spin-off of the biosciences business is completed, as expected or at all, and the timing of any such spin-off; whether the conditions to the spin-off can be satisfied; and general market and economic conditions. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Vice President, Global Public Affairs and Corporate Responsibility 240-631-3394 [email protected]
